Table 6.

Indices of test-retest reliability, smallest detectable difference (SDD) and minimal important difference (MID).

ICCSEMSDDMID
Pain (Likert)MSDBetween day 2 and 50.560.511.411
Between day 5 and 80.800.421.172
Pfizer*Between 2 and 4 h0.810.391.08
Between 2 and 8 h0.720.501.39
Between 2 and 12 h0.600.621.72
PfizerBetween day 1 and 90.070.762.12
Between day 2 and 90.150.762.12
Between day 5 and 90.590.541.502
NovartisBaseline to 7 days postdose0.350.852.361.0
24 h postdose to 7 days0.550.641.77
48 h postdose to 7 days0.710.491.36
Pain (VAS)NovartisBaseline to 7 days postdose0.353.6610.1519
24 h postdose to 7 days0.572.938.12
48 h postdose to 7 days0.762.236.18
Joint tendernessMSDBetween day 2 and day 50.500.461.282
Between day 5 and day 80.790.340.941
PfizerBetween Day 1 and 90.060.661.82
Between Day 5 and 90.110.591.62
NovartisBaseline to 7 days postdose0.0**1.062.931.0
24 h postdose to 7 days0.500.541.51
48 h postdose to 7 days0.490.541.50
72 h postdose to 7 days0.490.541.50
Joint swellingMSDBetween day 2 and day 50.480.531.471
Between day 5 and day 80.770.431.181
PfizerBetween Day 1 and 90.130.641.81
Between Day 5 and 90.370.732.01
NovartisBaseline to 7 days0.01.072.971
24 h postdose to 7 days0.440.651.80
48 h postdose to 7 days0.440.651.79
72 h postdose to 7 days0.440.651.79
Activity limitationsNovartis0.550.451.250.5
  • * Pain assessed as “current” level of pain;

  • pain assessed as “over the last 24 h;”

  • ** Statistical software indicated that estimation of a negative variance parameter was attempted. MSD: Merck Sharp & Dohme Corp.; VAS: visual analog scale; ICC: intraclass correlation; SEM: standard error of measurement.